CSLT · Castlight Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $34.78M | $35.60M | $35.06M | - | $35.08M | $35.50M | $39.05M | - | $35.46M | $35.91M |
| Cost of Revenue | $11.76M | $12.16M | $12.76M | - | $11.89M | $12.76M | $14.47M | - | $14.50M | $15.73M |
| Gross Profit | $23.02M | $23.45M | $22.30M | - | $23.19M | $22.74M | $24.57M | - | $20.96M | $21.75M |
| R&D | $11.63M | $12.32M | $12.11M | - | $11.18M | $13.04M | $13.82M | - | $14.29M | $14.49M |
| SG&A | $6.20M | $6.37M | $6.37M | - | $6.34M | $6.34M | $6.58M | - | $6.44M | $7.01M |
| Total Operating Expenses | $24.91M | $25.89M | $25.39M | - | $23.68M | $27.07M | $81.17M | - | $30.56M | $30.39M |
| D&A | $600.0K | $600.0K | $1.62M | - | $700.0K | $600.0K | $1.53M | - | $500.0K | $500.0K |
| Operating Income | ($1.89M) | ($2.44M) | ($3.09M) | - | ($490.0K) | ($4.33M) | ($56.60M) | - | ($9.60M) | ($8.64M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.03M) | ($2.39M) | ($3.00M) | - | ($447.0K) | ($4.20M) | ($56.34M) | - | ($9.34M) | ($8.38M) |
| EPS - Basic | $0.00 | ($0.02) | - | - | - | - | - | - | - | - |
| EPS - Diluted | $0.00 | ($0.02) | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $65.77M | $60.71M | $56.50M | $49.24M | $46.80M | $44.27M | $37.68M | $43.02M | $36.04M | $50.05M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.54M | $3.73M | $4.38M | $5.14M | $4.70M | $8.61M | $13.30M | $19.60M | $11.99M | $11.36M |
| Current Assets | $96.11M | $91.16M | $88.31M | $84.78M | $81.67M | $83.09M | $87.02M | $95.47M | $95.97M | $101.99M |
| Total Assets | $164.36M | $162.11M | $166.14M | $166.77M | $167.96M | $172.27M | $180.68M | $242.78M | $246.79M | $257.07M |
| Current Liabilities | $32.65M | $32.09M | $35.27M | $34.31M | $35.59M | $41.51M | $47.21M | $54.91M | $52.11M | $54.30M |
| Long-term Debt | - | - | - | $0 | $0 | $465.0K | $930.0K | $1.40M | $1.86M | $2.32M |
| Total Liabilities | $37.27M | $36.85M | $41.78M | $42.91M | $45.90M | $53.11M | $60.59M | $69.91M | $66.49M | $70.56M |
| Stockholders' Equity | $127.09M | $125.25M | $124.36M | $123.87M | $122.06M | $119.16M | $120.10M | $172.87M | $180.30M | $186.51M |
| Retained Earnings | ($524.64M) | ($522.61M) | ($520.22M) | ($517.23M) | ($516.03M) | ($515.58M) | ($511.38M) | ($455.04M) | ($443.30M) | ($433.96M) |
Cash Flow
| Line item | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $7.58M | - | - | - | ($14.36M) | - | - | - |
| Investing Cash Flow | - | - | ($212.0K) | - | - | - | $9.15M | - | - | - |
| Financing Cash Flow | - | - | ($104.0K) | - | - | - | ($124.0K) | - | - | - |
| CapEx | - | - | $212.0K | - | - | - | $1.26M | - | - | - |
| Free Cash Flow | - | - | $7.36M | - | - | - | ($15.62M) | - | - | - |
Ratios
| Metric | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 66.2% | 65.9% | 63.6% | - | 66.1% | 64.1% | 62.9% | - | 59.1% | 60.6% |
| Operating margin | -5.4% | -6.9% | -8.8% | - | -1.4% | -12.2% | -145.0% | - | -27.1% | -24.1% |
| EBITDA margin | -3.7% | -5.2% | -4.2% | - | 0.6% | -10.5% | -141.0% | - | -25.7% | -22.7% |
| Net margin | -5.8% | -6.7% | -8.5% | - | -1.3% | -11.8% | -144.3% | - | -26.3% | -23.3% |
| Free cash flow margin | - | - | 21.0% | - | - | - | -40.0% | - | - | - |
| FCF / Net income | - | - | -2.46 | - | - | - | 0.28 | - | - | - |
| R&D / Revenue | 33.4% | 34.6% | 34.6% | - | 31.9% | 36.7% | 35.4% | - | 40.3% | 40.3% |
| SG&A / Revenue | 17.8% | 17.9% | 18.2% | - | 18.1% | 17.9% | 16.8% | - | 18.2% | 19.5% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -1.2% | -1.5% | -1.8% | - | -0.3% | -2.4% | -31.2% | - | -3.8% | -3.3% |
| Return on equity | -1.6% | -1.9% | -2.4% | - | -0.4% | -3.5% | -46.9% | - | -5.2% | -4.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.94 | 2.84 | 2.50 | 2.47 | 2.29 | 2.00 | 1.84 | 1.74 | 1.84 | 1.88 |
| Quick ratio | 2.94 | 2.84 | 2.50 | 2.47 | 2.29 | 2.00 | 1.84 | 1.74 | 1.84 | 1.88 |
| Cash ratio | 2.01 | 1.89 | 1.60 | 1.44 | 1.32 | 1.07 | 0.80 | 0.78 | 0.69 | 0.92 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt / Assets | - | - | - | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt / EBITDA | - | - | - | - | 0.00 | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.29 | 1.29 | 1.34 | 1.35 | 1.38 | 1.45 | 1.50 | 1.40 | 1.37 | 1.38 |
| Liabilities / Assets | 0.23 | 0.23 | 0.25 | 0.26 | 0.27 | 0.31 | 0.34 | 0.29 | 0.27 | 0.27 |
| Efficiency | ||||||||||
| Asset turnover | 0.21 | 0.22 | 0.21 | - | 0.21 | 0.21 | 0.22 | - | 0.14 | 0.14 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 141d | 112d | 125d | - | 144d | 246d | 335d | - | 302d | 263d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -0.9% | 0.3% | -10.2% | - | -1.1% | -1.1% | 10.0% | - | -11.4% | - |
| Revenue CAGR (3y) | -4.6% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -0.7% | 3.1% | -9.2% | - | 10.6% | 4.6% | 14.9% | - | -17.0% | -1.4% |
| Operating income growth (YoY) | -284.7% | 43.5% | 94.5% | - | 94.9% | 49.9% | -421.5% | - | -28.5% | 38.6% |
| Net income growth (YoY) | -354.6% | 43.2% | 94.7% | - | 95.2% | 49.8% | -434.5% | - | -28.5% | 40.0% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | -26.7% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 4.1% | 5.1% | 3.6% | -28.3% | -32.3% | -36.1% | -36.7% | -11.2% | -6.4% | -4.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Product / service
$146.71M totalSubscription And Circulation$141.16M · 96.2%
Professional Services And Other$5.55M · 3.8%
Peer comparison
Same SIC group: Services-Computer Processing & Data Preparation
Comparing CASTLIGHT HEALTH against the 5 most active filers in the same SIC group.